NCT07414784

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

A Phase 1 Drug-Drug Interaction Study of ABBV-295, Levonorgestrel, and Ethinyl Estradiol in Healthy Adult Female Subjects With Overweight or Obesity

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: AbbVie · Industry
• Sex: Female
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This Study of ABBV-295 subcutaneous injections will assess pharmacokinetics and adverse events in healthy adult women participants with overweight or obesity taking oral contraceptives.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	ABBV-295	Subcutaneous Injections
DRUG	Levonorgestrel/Ethinyl Estradiol	Oral Tablet

Timeline

• Start date: 2026-02-11
• Primary completion: 2026-07-01
• Completion: 2026-07-01
• First posted: 2026-02-17
• Last updated: 2026-02-17

Locations

1 site across 1 country: United States